|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 782.50 DKK | +0.03% |
|
+0.86% | +12.09% |
| 10:08am | NOVO NORDISK : Gets a Sell rating from Jefferies | ZD |
| 12:00am | Eikonizo Therapeutics, Inc. announced that it has received funding from Novo Nordisk A/S | CI |
| Capitalization | 3,461B 491B 464B 431B 384B 694B 41,675B 760B 5,354B 1,976B 17,100B 1,844B 1,804B 74,176B | P/E ratio 2024 * |
34.6x | P/E ratio 2025 * | 27.6x |
|---|---|---|---|---|---|
| Enterprise value | 3,479B 494B 467B 433B 386B 697B 41,888B 764B 5,381B 1,987B 17,187B 1,854B 1,813B 74,556B | EV / Sales 2024 * |
12.1x | EV / Sales 2025 * | 10x |
| Free-Float |
-
| Yield 2024 * |
1.44% | Yield 2025 * | 1.87% |
More valuation ratios
* Estimated data
More news
Last Transcript: Novo Nordisk A/S
More recommendations
More press releases
More news
| 1 day | +1.00% | ||
| 1 week | +1.06% | ||
| Current month | +4.40% | ||
| 1 month | +2.16% | ||
| 3 months | -9.68% | ||
| 6 months | -20.01% | ||
| Current year | +13.25% |
1 week
761.10
798.10
1 month
697.80798.10
Current year
688.801 033.20
1 year
645.001 033.20
3 years
302.201 033.20
5 years
165.851 033.20
10 years
109.101 033.20
| Director | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 58 | 31/12/2016 | |
| Director of Finance/CFO | 53 | 14/02/2018 | |
| Chief Tech/Sci/R&D Officer | 54 | 31/12/2018 |
| Manager | Title | Age | Since |
|---|---|---|---|
Sylvie Grégoire
BRD | Director/Board Member | 62 | 18/03/2015 |
Kasim Kutay
BRD | Director/Board Member | 59 | 22/03/2017 |
Helge Lund
CHM | Chairman | 62 | 21/03/2018 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 21.31% | 203 M€ | +14.97% | ||
| 10.45% | 4 M€ | +18.93% | ||
| 5.40% | 20 M€ | +16.38% | - |
| Change | 5d. change | 1-year change | 3-years change | Capi. ($) | ||
|---|---|---|---|---|---|---|
| +1.02% | +1.06% | +18.14% | +110.55% | 491B | ||
| -2.80% | +0.47% | +34.37% | +230.83% | 724B | ||
| +0.19% | -3.36% | -3.12% | -9.83% | 360B | ||
| +0.22% | -2.86% | +18.28% | +42.22% | 312B | ||
| +0.68% | +3.16% | +0.04% | +42.45% | 263B | ||
| -0.45% | +0.43% | +0.51% | -32.20% | 236B | ||
| -0.08% | -1.20% | +5.59% | +30.11% | 212B | ||
| +0.02% | -3.93% | +4.42% | +19.69% | 204B | ||
| +1.85% | -0.17% | +3.16% | +30.61% | 149B | ||
| +1.44% | +1.08% | -9.31% | -49.88% | 148B | ||
| Average | +0.12% | -0.66% | +7.21% | +41.45% | 309.81B | |
| Weighted average by Cap. | +0.30% | -0.43% | +12.80% | +78.14% |
| 2024 * | 2025 * | |
|---|---|---|
| Net sales | 287B 40.68B 38.45B 35.67B 31.81B 57.45B 3,452B 62.94B 443B 164B 1,416B 153B 149B 6,144B | 345B 48.95B 46.26B 42.92B 38.27B 69.12B 4,153B 75.73B 534B 197B 1,704B 184B 180B 7,392B |
| Net income | 101B 14.36B 13.57B 12.59B 11.23B 20.28B 1,218B 22.22B 157B 57.79B 500B 53.92B 52.75B 2,169B | 125B 17.76B 16.79B 15.57B 13.89B 25.08B 1,507B 27.48B 194B 71.47B 618B 66.7B 65.24B 2,682B |
| Net Debt | 17.73B 2.52B 2.38B 2.21B 1.97B 3.55B 213B 3.89B 27.42B 10.12B 87.57B 9.45B 9.24B 380B | -468M -66.4M -62.76M -58.22M -51.92M -93.77M -5.63B -103M -724M -267M -2.31B -249M -244M -10.03B |
More financial data
* Estimated data
Employees
71,880
Sector
Pharmaceuticals
Calendar
05/02/2025
- Q4 2024 Earnings Release
| Date | Price | Change | Volume |
|---|---|---|---|
| 10/12/24 | 782.50 kr | +0.03% | 2,670,040 |
| 09/12/24 | 782.30 kr | -0.41% | 2,367,910 |
| 06/12/24 | 785.50 kr | +1.88% | 2,421,773 |
| 05/12/24 | 771.00 kr | -1.15% | 2,488,660 |
| 04/12/24 | 780.00 kr | -0.29% | 3,468,775 |
Delayed Quote Nasdaq Copenhagen, December 10, 2024 at 02:13 pm
More quotes
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
23
Last Close Price
782.30DKK
Average target price
938.17DKK
Spread / Average Target
+19.93%
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- NOVO B Stock
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition